
TY  - JOUR
A1  - Tietze, Lutz F. 
A1  - Feuerstein, Tim 
T1  - <emph type="2">Review:</emph> Highly Selective Compounds for the Antibody-Directed Enzyme Prodrug Therapy of Cancer
JF  - Australian Journal of Chemistry
JO  - Aust. J. Chem.
Y1  - 2003
VL  - 56
IS  - 9
SP  - 841
EP  - 854
KW  - 
UR  - https://doi.org/10.1071/CH03036 
N2  - Antibody-directed enzyme prodrug therapy (ADEPT) is a recent development for a selective treatment of cancer, based on site-directed formation at the surface of malignant cells of cytotoxic compounds from non-toxic prodrugs with a conjugate of an appropriate enzyme and a monoclonal antibody which binds to tumour-associated antigens. New potent prodrugs of analogues of the antibiotic CC-1065 have been developed. These show a remarkable selectivity with a Q(IC50) value of up to more than 3000. Moreover, the formed drug has a high potency with an IC50 of 30 pM. 
ER  -

